3rd LNP Immunogenicity and Toxicity Summit

With the applications of LNPs rapidly expanding beyond vaccines, as well as beyond the liver, it is of utmost importance to predict and minimize adverse reactions to guarantee patient safety in the clinic, especially following a clinical hold on Verve Therapeutics' gene therapy earlier this year, due to safety concerns surrounding the LNP delivery system.

Returning in December, the 3rd LNP Immunogenicity and Toxicity Summit will return as your unique forum uniting industry experts striving to measure, predict and monitor non-clinical and clinical safety risk for lipid nanoparticles to ensure regulatory compliance for vaccines, gene and cell therapies.

Join experts from Pfizer, AstraZeneca, Moderna, BioNTech and Beam Therapeutics, as they dive deep into mechanisms of toxicity, optimal delivery strategy, PEG-lipid alternatives and in vitro prediction, to progress development of safer LNP-delivered therapeutics.

URLs:
Website: https://go.evvnt.com/2609743-0?pid=10018
Tickets: https://go.evvnt.com/2609743-2?pid=10018
Brochure: https://go.evvnt.com/2609743-3?pid=10018

Prices:
Full Access Pass (Conference + Workshop Day) - Drug Developer Pricing: USD 4197.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Full Access Pass (Conference + Workshop Day) - Academic Pricing: USD 3597.00,
Conference Only - Academic Pricing: USD 2599.00,
Full Access Pass (Conference + Workshop Day) - Service Provider Pricing: USD 5097.00,
Conference Only - Service Provider Pricing: USD 3699.00

Speakers: Ana J Narvaez, Director Translational Biology, Moderna, Bin Wu, Founder and Chief Executive Officer, Cytodigm, Daniel Serna, Principal Research Scientist, Abbvie, Dimitrios Bitounis, Scientist, Investigative Toxicology, Sanofi, Heinrich Haas, Chief Technology Officer, NeoVac, Jason Pennucci, Director, Bioanalytical Sciences, Moderna, Julien Couture-Senecal, Co-Founder, Azane Therapeutics, Kelly Colletti, Director - Preclinical Bioanalytics, Beam Therapeutics, Kevin Sun, Assistant Professor, Icahn School of Medicine at Mount Sinai, Liping Zhou, Senior Director, Advanced Drug Delivery, AstraZeneca, Maja Sedic, Senior Director, Toxicology, Orna Therapeutics, Mohammad Shadid, Vice President, Translational Sciences, Korro Bio, Natalia Martin, Orozco Chief Scientific Officer, Providence Therapeutics, Nina Neblung, Non-clinical Safety Manager, BioNTech SE, Qi-Ying Hu, Chief Executive Officer, Corti Therapeutics, Randall Moreadith, Chief Development Officer, Serina Therapeutics, Sean Semple, Vice President - Preclinical Development, Acuitas Therapeutics, Smanla Tundup, Director - Research and Development, Eli Lilly and Co., Sophie Tourdot, Associate Research Fellow, Immunogenicity Sciences Lead, Pfizer, Umberto Capasso Palmiero, Senior Scientist,Non - Viral Delivery, Global Nucleic Acid Therapies, Novo Nordisk